Search Results
Your search for Hope matches 3227 pages
Showing 101 - 150Mark Cuban Does It Again: Reshuffling the Deck of Front-Line CML Therapy
With the currently available BCR::ABL1 tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has transformed from an invariably fatal disorder (10-year overall survival < 10%) to an indolent one, associated with a near-normal life expectancy on optimal tyrosine kinase inhibitor...
Use of Niraparib in Patients With Advanced Melanoma
Researchers may have uncovered early indications of the clinical benefit of niraparib in patients with advanced melanoma whose tumors have specific genetic changes impacting DNA repair, according to a recent study published by Kim et al in JCO Precision Oncology. Background The U.S. Food and Drug...
I Have Stage IV Lung Cancer and Still Consider Myself the Luckiest Man in the World
Although I have spent the past 2 decades of my medical career as a primary care physician, educator, and researcher in conditions that disproportionately affect people of Asian descent, including lung cancer, I was still unprepared to hear the words “You have stage IV non–small cell lung...
Bringing Evidence-Based Integrative Medicine Into Everyday Oncology Practice
Despite the significant rise over the past 50 years in the use of evidence-based integrative medicine in conjunction with conventional cancer treatments—up from just 20% in the 1970s to about 80% in 20171—training opportunities in the fundamentals of this emerging field within the specialty of...
W. Kimryn Rathmell, MD, PhD, FASCO, Named CEO of OSUCCC-James
Following a comprehensive national search, W. Kimryn Rathmell, MD, PhD, FASCO, former Director of the National Cancer Institute (NCI), has accepted the role of Chief Executive Officer (CEO) of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J....
The Power of Translational Science to Transform the Lives of Patients Worldwide
Despite a 30-year history as an ASCO volunteer, for Eric J. Small, MD, FASCO, this past year as President-Elect has opened new perspectives on the organization he will soon lead as ASCO’s 62nd President, effective during the 2025 ASCO Annual Meeting, May 30–June 3, 2025, in Chicago. After serving...
Circulating Tumor DNA–Guided Risk Stratification in Colorectal Cancer: Evolving Evidence and Future Utility
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker in colorectal cancer, offering dynamic insight into disease burden and recurrence risk. However, questions remain about its clinical utility and optimal application, as well as its equitable access across practice settings. At the...
AI Model Estimates Biological Age and Predicts Survival in Patients With Cancer
FaceAge, a deep learning system, was developed and validated to estimate biological age from photographs of faces. In a study published in The Lancet Digital Health, FaceAge showed the ability to predict short-term outcomes in patients with cancer. The study demonstrated that FaceAge could...
Overall Survival Analysis in CodeBreaK 300: Sotorasib Plus Panitumumab vs Investigator’s Choice in Chemorefractory KRAS G12C Colorectal Cancer
As reported in the Journal of Clinical Oncology by Pietrantonio et al, overall survival analysis in the phase III CodeBreaK 300 trial showed numeric improvement with sotorasib/panitumumab vs investigator's choice of treatment in patients with chemorefractory KRAS G12C-mutant metastatic colorectal...
How Could So Many Physicians Have Failed Me?
The first sign that something was terribly wrong was in 2015, when I began to feel so fatigued that it was difficult to get out of bed even after 8 to 10 hours of sleep. I’ve been full of energy my whole life and couldn’t understand why I was so tired all the time. Then I began to experience...
Keith T. Flaherty, MD, FAACR, Elected as AACR President-Elect for 2025–2026
The members of the American Association for Cancer Research (AACR) have elected Keith T. Flaherty, MD, FAACR, as the AACR President-Elect for 2025–2026. He will assume the Presidency in April 2026 at the AACR Annual Meeting in San Diego. Dr. Flaherty is Director of Clinical Cancer Research and the ...
ASH Studies Bolster Support for Menin Inhibitor in Acute Leukemia
The recent approval of the oral menin inhibitor revumenib brought much-needed treatment to patients with a challenging subset of disease: adults and children with relapsed or refractory acute leukemia harboring a lysine methyltransferase 2A gene (KMT2A) translocation or rearrangement. Approval was...
AML: MRD Testing Led to Survival Benefits in Subset of Patients
Sequential molecular measurable residual disease (MRD) testing and monitoring led to a survival benefit among younger patients with acute myeloid leukemia (AML) and NPM1 and FLT3-ITD mutations, according to the results of a study published in The Lancet Haematology. Patients with both mutations...
Cannabis Use Disorder Significantly Increases Mortality Risk in Colorectal Cancer
Patients with colorectal cancer and a history of cannabis use disorder had a more than 20 times higher risk of mortality within 5 years than those without cannabis use order, according to the results of a study published in Annals of Epidemiology. The 5-year mortality rate in patients with a...
AACR 2025: Novel CAR T-Cell Therapy Induces Response in Patients With Advanced Thyroid Cancers
A novel chimeric antigen receptor (CAR) T-cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer. Results from a small, first-in-human phase I trial were presented at the ...
DDW 2025: Genetic Mutations Linked to Worse Stomach Cancer Outcomes
Using next-generation DNA sequencing, researchers have identified four specific genes whose mutations are linked to the development and progression of lethal stomach cancers. This could potentially enable practitioners to offer targeted treatments that would spare many patients from unnecessarily...
AACR 2025: Using Single-Cell RNA Sequencing to Evaluate Cell States in AML
A new gene-expression atlas developed using single-cell RNA sequencing data sheds light on how normal hematopoietic cells differentiate and was used to catalog the multiple ways aberrant differentiation can lead to acute myeloid leukemia (AML). Andy G.X. Zeng, PhD, an MD/PhD candidate at the...
AACR 2025: Molecularly Selected, Tumor-Agnostic Phase II Trial Focuses on Combination Therapy
According to the results of a molecularly matched, tumor-agnostic phase II trial, the combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab demonstrated antitumor activity with no new safety signals, particularly in patients with BRCA1/2 mutations. Data from this...
AACR 2025: AI-Driven Analysis of Digital Pathology Images May Improve Sarcoma Subtyping Among Pediatric Patients
A novel artificial intelligence (AI)-based model could accurately classify sarcomas among pediatric patients using digital pathology images alone, according to new findings presented by Thiesen et al at the 2025 American Association for Cancer Research (AACR) Annual Meeting (Abstract 2423/8)....
AACR 2025: Pretrained AI Models Could Help Accurately Diagnose Nonmelanoma Skin Cancers in Resource-Limited Settings
Artificial intelligence (AI) models pretrained on vast data sets may outperform standard baseline models in identifying nonmelanoma skin cancers from digital images of tissue samples, according to new findings presented by Song et al at the 2025 American Association for Cancer Research (AACR)...
Richard Pazdur, MD, Honored With 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine
During the 2025 American Association for Cancer Research (AACR) Annual Meeting, Richard Pazdur, MD, Director of the Oncology Center of Excellence at the U.S. Food and Drug Administration (FDA), accepted the 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine...
AACR 2025: Nonoperative Management of Mismatch Repair–Deficient Tumors
PD-1 blockade with the PD-1 inhibitor dostarlimab-gxly induced complete tumor clearance and resolved the need for surgery in patients with locally advanced, mismatch repair–deficient (dMMR) cancers, according to preliminary results from a phase II trial presented at the 2025 American Association...
Childhood Exposure to Bacterial Toxin May Trigger Early-Onset Colorectal Cancer
Researchers may have identified the bacterial toxin colibactin as a potential factor contributing to the concerning rise in early-onset colorectal cancer, according to a novel study published by Díaz-Gay et al in Nature. The findings demonstrated a substantial enrichment of colibactin-related...
W. Kimryn Rathmell, MD, PhD, FASCO, Named CEO of The Ohio State’s James Cancer Hospital and Solove Research Institute
Following a comprehensive national search, W. Kimryn Rathmell, MD, PhD, FASCO, former Director of the National Cancer Institute (NCI), has accepted the role of Chief Executive Officer (CEO) of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J....
ASCO Updates Guideline for Fertility Preservation in People With Cancer
ASCO has released an update to the guideline for fertility preservation in people with cancer. The update, recently published in the Journal of Clinical Oncology,1 provides recommendations regarding evaluation and counseling for fertility preservation; methods and timing of fertility preservation;...
Response to Immune Checkpoint Inhibitors Not Affected by Age
Older patients with a solid tumor responded with similar clinical outcomes to younger patients treated with immune checkpoint inhibitors, the results of a study published in Nature Communications showed. However, older patients did have divergent immune phenotypes compared with younger patients,...
Renowned Breast Cancer Physician-Scientist Hope S. Rugo, MD, FASCO, to Lead Women’s Cancers Program at City of Hope
Hope S. Rugo, MD, FASCO, recently joined the staff of City of Hope as the new Director of the Women’s Cancers Program, Division Chief of Breast Medical Oncology, and Professor in the Department of Medical Oncology and Therapeutics Research. In her role, she will lead and enhance City of Hope’s...
Novel Drug/Device Combination May Improve Outcomes in Metastatic Uveal Melanoma
Percutaneous hepatic perfusion using a melphalan hepatic delivery system (melphalan/HDS) may be an effective treatment option in patients with unresectable uveal melanoma that has metastasized to the liver, according to a recent study published by Zager et al in the Annals of Surgical Oncology....
Link Between CT Scans and Future Cancer Incidence?
At current use and radiation dose levels, computed tomography (CT) scans may eventually account for 5% of all cancers annually, according to a recent modeling study published by Smith-Bindman et al in JAMA Internal Medicine. The danger is greatest for infants, followed by children and...
Immunotherapy, Radiosurgery Combination and Risk of Radiation Necrosis in Patients With Cancer Who Have Brain Metastases
Patients with melanoma and lung cancer who have brain metastases may experience severe inflammatory reactions after receipt of immunotherapy drugs combined with radiation therapy, according to a recent study published by Vaios et al in JAMA Network Open. Study Methods and Results In this study,...
Crossing State Borders: Addressing Residential Barriers to Cancer Care
A high proportion of Medicare beneficiaries cross state borders to access cancer care, particularly patients residing in rural areas, according to a recent study published by Moen et al in JAMA Network Open. The findings have significant implications for telehealth policies and physician licensure, ...
NK Cells Complexed With Bispecific Antibody May Be of Benefit to Patients With Lymphoma
A novel cell therapy approach using cord blood–derived natural killer (NK) cells precomplexed with the CD30/CD16A bispecific antibody AFM13 may be safe and generate responses in patients with refractory CD30-positive lymphomas, according to a recent study published by Nieto et al in Nature...
Machine Learning Program May Enhance Transplantation Risk Assessment in Patients With Myelofibrosis
A novel machine learning model may outperform standard statistical models in identifying and stratifying transplantation risk among patients with myelofibrosis, according to a recent study published by Hernández-Boluda et al in Blood. Background Although there are several therapies available to...
Breast Shrinkage Following Breast-Conserving Therapy
Breast-conserving therapy, including radiation therapy, could lead to a progressive reduction in breast size over time among women with early-stage breast cancer, according to a recent study published by Becker et al in Plastic and Reconstructive Surgery. Background Breast-conserving...
Bringing Palliative Care to Every Patient With Cancer
Janet L. Abrahm, MD, FACP, FAAHPM, FASCO, has spent more than half of her oncology career as a palliative care physician. After receiving her medical degree from the University of California, San Francisco (UCSF), in 1973, Dr. Abrahm completed her internship and residency at Massachusetts General...
Race-Associated Molecular Differences and Treatment Response in Pancreatic Cancer
Investigators studied race-associated molecular differences in the pancreatic tumors of Black and White patients to determine whether such differences were associated with response to immunotherapy. The findings were published recently by Mandal et al in Cancer Research Communications and reinforce ...
Neoadjuvant Combination Immunotherapy for Head and Neck Cancer
A combination of two immunotherapies may improve treatment response among patients with head and neck squamous cell carcinomas compared with just one immunotherapy drug, according to a recent study published by Li et al in Cancer Cell. Background Head and neck squamous cell carcinomas occur in the...
Combination Therapy Could Help Overcome Drug Resistance in Patients With KRAS-Mutated NSCLC
Researchers have uncovered a novel combination therapy leveraging the U.S. Food and Drug Administration (FDA)-approved KRAS inhibitor sotorasib and an experimental drug called FGTI-2734, which could improve the efficacy of precision medicine in patients with KRAS-mutated non–small cell lung cancer...
Two Decades of Collaboration: The Accelerating Anticancer Agent Development and Validation (AAADV) Workshop
Over the past 20 years, the investment in research and development of cancer therapies has been unprecedented, and the pace of new drug development has been accelerating. To illustrate this trajectory, the U.S. Food and Drug Administration (FDA) approved 71 treatments for solid cancers in adults...
Novel Nanoliposome Radiotherapeutic May Enhance Survival in Patients With Glioblastoma
The investigational drug formulation rhenium (Re)-186 obisbemeda (RNL-186) may extend survival in patients with glioblastoma, according to a recent study published by Brenner et al in Nature Communications. Background Glioblastoma is the most common primary brain tumor in adult patients. The median ...
ACS Awards Dr. W. Kimryn Rathmell the 2025 Medal of Honor
In recognition of her commitment to tackling the complexities and challenges of cancer, the American Cancer Society (ACS) awarded the 2025 Medal of Honor to W. Kimryn Rathmell, MD, PhD, MMHC. The Medal of Honor is the American Cancer Society’s most prestigious award given to distinguished...
Greater Plant-Based Oil, Lower Butter Intake Could Improve Risk of Cancer-Related Mortality
Investigators have found that the consumption of plant-based oils instead of butter may provide beneficial health effects and potentially reduce the risk of premature mortality, according to recent findings presented at the American Heart Association Epidemiology, Prevention, Lifestyle &...
How the Cancer Moonshot Is Making a Difference for Patients Here and Across the World
Catharine Young, PhD, has spent the past decade of her career focused on cancer policy and advocacy. A native of Johannesburg, South Africa, Dr. Young served as Senior Director of Science Policy at the Biden Cancer Initiative, which began in 2017 by then former Vice President Joe Biden. There she...
SGLT2 Inhibitors Could Help Protect Against Heart Failure in Patients With Cancer
A common type of diabetes drug known as sodium-glucose cotransporter-2 (SGLT2) inhibitors could help patients with cancer achieve greater long-term recovery, according to a novel study published by Bhalraam et al in the European Journal of Preventive Cardiology. Background Many patients with cancer ...
Combination of MCL-1 and SRC Inhibitors May Increase Cell Death in AML
An innovative combination of treatment strategies involving myeloid cell leukemia (MCL)-1 inhibitors and a kinase inhibitor targeting the SRC oncogene could be effective at triggering cell death in acute myeloid leukemia (AML) cells, according to a recent study published by Hu et al in Signal...
Cabozantinib/Atezolizumab in Locally Advanced or Metastatic Urothelial Carcinoma
In a multicohort phase Ib study (COSMIC-021) reported in the Journal of Clinical Oncology, Sumanta K. Pal, MD, FASCO, and colleagues identified the activity of cabozantinib plus atezolizumab in a cohort of patients with locally advanced or metastatic urothelial carcinoma according to first-line...
Text Message Platform May to Help Address ‘Time Toxicity’ in Patients With Cancer
Digital technology may help to safely reduce the amount of time some patients with cancer spend receiving care—also referred to as “time toxicity”—according to a recent study published by Bange et al in NEJM Catalyst. Background Patients with cancer often spend a large amount of time on activities...
Influencing Geriatric Oncology Practice Worldwide: 2024 International Society of Geriatric Oncology Conference
The Annual Meeting of the International Society of Geriatric Oncology (SIOG) was held from October 17–19, 2024, in Montreal. The conference theme was “Promoting Equity and Enhancing Optimal Care Delivery.” The conference chairs were Shabbir Alibhai, MD, MSc, FRCPC, and Martine Puts, RN, PhD, FAAN,...
Are Immune Checkpoint Inhibitors Effective in Hospitalized Patients With Cancer?
Immune checkpoint inhibitors may be ineffective among patients hospitalized with cancer, according to a recent study published by Riaz et al in JCO Oncology Practice. Background Immune checkpoint inhibitors have transformed treatment for many cancer types but are often restricted for inpatient use...
Flagellin and Immune Checkpoint Inhibition in Patients With Ovarian Cancer
The interference of gut bacteria could explain the ineffectiveness of immune checkpoint therapy in some patients with ovarian cancer, according to a recent study published by McGinty et al in Cancer Immunology Research. Background There are over 10,000 ovarian cancer–related deaths in the United...
